InvestorsHub Logo


04/27/23 8:00 AM

#732 RE: DewDiligence #724

ABBV reports 1Q23 results—raises non-GAAP EPS guidance:

2023 non-GAAP EPS has been raised $0.10 at both the lower and upper bounds of the range, which is now $10.72-$11.12. This a sharp decline from 2022’s $13.77 due to the launch of Humira biosimilars in the US market.